# Latigo Biotherapeutics, Inc.: overview

LTGO · Nasdaq · CIK 2056611 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ltgo.md) · [Financials](/companies/ltgo/financials.md) · [Filings](/companies/ltgo/filings.md) · [Insiders](/companies/ltgo/insiders.md)

Revenue is not reported in this company’s XBRL financial statements.

## Last eight quarters

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | period not labelled (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Revenue | $ | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | not reported | [(36.52)](/filings/0001193125-26-381969.md) | not reported | [(27.59)](/filings/0001193125-26-381969.md) |
| Free cash flow | $ | not reported | not reported | not reported | not reported |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL not reported.

## Last five fiscal years

Not reported.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ltgo/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

None of the funds in coverage reports a position in its latest 13F.

## Recent filings

[All 39 filings](/companies/ltgo/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-03 | 16:32 ET | [10-Q](/filings/0001193125-26-381969.md) | Quarterly report, period 2026-06-30 | 0001193125-26-381969 |
| 2026-09-03 | 16:15 ET | [8-K](/filings/0001193125-26-381912.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-381912 |
| 2026-08-17 | 19:06 ET | [SCHEDULE 13D](/filings/0001104659-26-097980.md) | Ownership report, active investor | 0001104659-26-097980 |
| 2026-08-10 | 16:02 ET | [8-K](/filings/0001193125-26-342321.md) | 5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-342321 |
| 2026-08-04 | 21:54 ET | [S-1/A](/filings/0001193125-26-331205.md) | Registration statement, amended | 0001193125-26-331205 |
| 2026-08-03 | 06:06 ET | [S-1/A](/filings/0001193125-26-329431.md) | Registration statement, amended | 0001193125-26-329431 |
| 2026-07-17 | 12:33 ET | [S-1](/filings/0001193125-26-307306.md) | Registration statement | 0001193125-26-307306 |

## Latest annual report

No annual report is in coverage.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 2056611
- Tickers: LTGO
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 18:05 ET. No prices; not investment advice.